期刊
CORNEA
卷 21, 期 6, 页码 592-597出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00003226-200208000-00012
关键词
corneal transplantation; CD40-CD154 costimulation; ocular anti-CD154 therapy; graft survival; corneal neovascularization
资金
- PHS HHS [NEI-12963] Funding Source: Medline
Purpose. To determine the effect of ocular administration of anti-CD154 monoclonal antibody on the survival of orthotopic murine corneal transplants. Methods. BALB/c mice were used as recipients of multiple minor H- and MHC- mismatched orthotopic corneal transplants. Recipient beds were either avascular (normal-risk) or neovascularized (high-risk) at the time of surgery. Mice were randomized to receive either anti-CD 154 antibody or control immunoglobulin by subconjunctival injection. All grafts were evaluated for signs of rejection by slitlamp biomicroscopy until week 20-24 with the therapy tapered and discontinued after week 8 and week 12, respectively. Results. In normal-risk transplantation. the 8-week survival rate improved from 30% in control mice to 90% in anti-CD154 treated mice (p = 0.0061). In high-risk transplantation. the survival rate of anti-CD154-treated mice was enhanced to 55% compared with 30% in control mice at week 8 (p = 0.0184) however, tapering and termination of anti-CD154 led to some loss in graft survival. with a survival rate of 56% in nor-mal-risk recipients, and 22% in high-risk recipients by week 20. Anti-CD40L treated animals displayed lower grades of postoperative corneal neovascularization (p<0.05), in particular in normal-risk recipients. Conclusions. Local ocular administration of anti-CD154 is effective in the prevention of corneal allograft rejection in normal-risk recipients, and in delaying the incidence of rejection in high-risk recipients. Long-term graft survival may not be fully achieved following termination of the CD40-CD154 pathway blockade.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据